pioglitazone has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 5.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| " Pioglitazone dosing protected TH-positive neurons, closely matching the number of PPAR-gamma expressing cells in the ipsilateral SNpc." | 1.40 | Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. ( Emborg, M; Swanson, C, 2014) |
| "Pioglitazone-treated monkeys also showed a dose-dependent modulation of CD68-ir inflammatory cells, that was significantly decreased for 5 mg/kg treated animals compared to placebo (P = 0." | 1.37 | The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. ( Bondarenko, V; Brunner, K; Emborg, ME; Joers, V; Johnson, JA; Kemnitz, JW; Simmons, HA; Swanson, CR; Ziegler, TE, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Swanson, C | 1 |
| Emborg, M | 1 |
| Swanson, CR | 1 |
| Joers, V | 1 |
| Bondarenko, V | 1 |
| Brunner, K | 1 |
| Simmons, HA | 1 |
| Ziegler, TE | 1 |
| Kemnitz, JW | 1 |
| Johnson, JA | 1 |
| Emborg, ME | 1 |
| Laloux, C | 1 |
| Petrault, M | 1 |
| Lecointe, C | 1 |
| Devos, D | 1 |
| Bordet, R | 1 |
| Breidert, T | 1 |
| Callebert, J | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Launay, JM | 1 |
| Hirsch, EC | 1 |
4 other studies available for pioglitazone and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Central Nervous System Age | 2014 |
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.
Topics: Animals; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Female; Hypoglycemic Agents; Inflammati | 2011 |
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Activit | 2012 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |